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TIMP‑3 facilitates binding 
of target metalloproteinases 
to the endocytic receptor LRP‑1 
and promotes scavenging 
of MMP‑1
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Matrix metalloproteinases (MMPs) and the related families of disintegrin metalloproteinases (ADAMs) 
and ADAMs with thrombospondin repeats (ADAMTSs) play a crucial role in extracellular matrix 
(ECM) turnover and shedding of cell‑surface molecules. The proteolytic activity of metalloproteinases 
is post‑translationally regulated by their endogenous inhibitors, known as tissue inhibitors of 
metalloproteinases (TIMPs). Several MMPs, ADAMTSs and TIMPs have been reported to be 
endocytosed by the low‑density lipoprotein receptor‑related protein‑1 (LRP‑1). Different binding 
affinities of these proteins for the endocytic receptor correlate with different turnover rates which, 
together with differences in their mRNA expression, determines their nett extracellular levels. 
In this study, we used surface plasmon resonance to evaluate the affinity between LRP‑1 and a 
number of MMPs, ADAMs, ADAMTSs, TIMPs and metalloproteinase/TIMP complexes. This identified 
MMP‑1 as a new LRP‑1 ligand. Among the proteins analyzed, TIMP‑3 bound to LRP‑1 with highest 
affinity  (KD = 1.68 nM). Additionally, we found that TIMP‑3 can facilitate the clearance of its target 
metalloproteinases by bridging their binding to LRP‑1. For example, the free form of MMP‑1 was 
found to have a  KD of 34.6 nM for LRP‑1, while the MMP‑1/TIMP‑3 complex had a sevenfold higher 
affinity  (KD = 4.96 nM) for the receptor. TIMP‑3 similarly bridged binding of MMP‑13 and MMP‑14 to 
LRP‑1. TIMP‑1 and TIMP‑2 were also found to increase the affinity of target metalloproteinases for 
LRP‑1, albeit to a lesser extent. This suggests that LRP‑1 scavenging of TIMP/metalloproteinase 
complexes may be a general mechanism by which inhibited metalloproteinases are removed from the 
extracellular environment.
Extracellular matrix (ECM) turnover is an important feature of several physiological processes, including devel-
opment, organogenesis, wound healing and tissue remodelling. The matrix metalloproteinases (MMPs) are a 
major class of proteinases involved in ECM  turnover1. The related disintegrin metalloproteinases (ADAMs) and 
ADAMs with thrombospondin motifs (ADAMTSs) are also involved in ECM turnover by processing of cell sur-
face molecules and various ECM components,  respectively2,3. Tissue inhibitors of metalloproteinases (TIMPs) 
are wedge-shaped proteins that regulate the activity of MMPs, ADAMs and ADAMTSs by interacting with 
the active site cleft of the enzymes and forming a tight complex with a 1:1  stoichiometry4. Under physiological 
conditions, ECM turnover is regulated by the balance between metalloproteinases and TIMPs, and disruption 
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of this balance is associated with pathological conditions characterised by enhanced ECM degradation, such as 
arthritis, cancer and cardiovascular  disorders5–7.
The expression of metalloproteinases and TIMPs can be regulated at different levels, ranging from regulation 
of their transcription by cytokines and growth factors, to post-transcriptional regulation by RNA interference. 
In addition, the catalytic activity of several metalloproteinases can be post-translationally activated by proteo-
lytic removal of their inhibitory pro-domain4,6. Moreover, a major mechanism that regulates the extracellular 
levels of several MMPs (including MMP-28, MMP-99 and MMP-1310,11) ADAMTSs (including ADAMTS-112, 
ADAMTS-413 and ADAMTS-514) and TIMPs (including TIMP-115, TIMP-28, TIMP-316,17) is endocytosis and 
subsequent lysosomal degradation via the scavenger receptor low-density lipoprotein receptor-related protein 
1 (LRP-1)8,9. LRP-1 is considered to be a master regulator of ECM turnover, since the affinity of individual 
metalloproteinases and TIMPs for LRP-1 determines their extracellular half-life and so controls the balance 
between ECM degradation and deposition. In this study, we used surface plasmon resonance (SPR) to carry out 
a systematic analysis of the affinity of several MMPs, ADAMs, ADAMTSs, TIMPs and metalloproteinase/TIMP 
complexes for LRP-1. This allowed us to investigate the hierarchy of LRP-1 ligands within the metalloproteinase 
activity network.
Among all proteins analyzed, we found that TIMP-3 bound to LRP-1 with the highest affinity. Furthermore, 
TIMP-3 was able to promote scavenging of its target enzymes, with TIMP-3/metalloproteinase complexes hav-
ing lower KD values for LRP-1 than observed for the enzymes alone. KD values for TIMP-3/metalloproteinase 
complexes were almost indistinguishable from that of TIMP-3 alone, indicating that the inhibitor can bridge 
the binding of metalloproteinases to LRP-1. TIMP-1 and TIMP-2 were also able to promote scavenging of their 
target enzymes, albeit to a lesser extent, indicating that TIMP-mediated scavenging may be a general mechanism 
by which inhibited metalloproteinases are cleared from the extracellular environment.
Experimental procedures
Materials and cells culture. HTB94 human chondrosarcoma cells were from American Culture Type 
Collection (Manassas, VA, USA), and maintained in DMEM with 10% FCS, 100 U/ml penicillin and 100 U/
ml streptomycin at 37 °C in 5%  CO2. Dulbecco’s modified Eagle’s medium (DMEM), l-glutamine, penicillin/
streptomycin, fetal calf serum (FCS), hygromycin B and trypsin–EDTA from PAA Laboratories (Somerset, UK); 
DMEM without L-glutamine, cysteine, methionine or cystine from MP Biomedicals (Solon, OH, USA). BSA 
was from Sigma-Aldrich (Dorset, UK); LRP-1 was from Biomac (Leipzig, Germany); ADAM10 and ADAM17 
ectodomain were from R&D Systems (Abingdon, UK). The catalytic domain of human MMP-1 (MMP-1ΔC), 
full length MMP-1 and MMP-1  E200A18; recombinant His-tagged  RAP14; FLAG-tagged ADAMTS-4 lacking 
the C-terminal spacer  domain19; FLAG-tagged ADAMTS-5 lacking the C-terminal thrombospondin domain 
and lacking the C-terminal thrombospondin and spacer  domains20; FLAG-tagged TIMP-3 and FLAG-tagged 
N-TIMP-321; TIMP-1 and TIMP-222; MMP-3 catalytic domain (MMP-3ΔC)23; MMP-924; MMP-13  E204A25 were 
prepared as previously described. The ectodomain of MMP-14 was expressed in E. coli BL21(DE3). Inclusion 
bodies were isolated and refolded as described by Huang et al.26. All MMPs were activated in vitro with APMA 
to remove the pro-domain, as previously  described27,33.
Inhibition of selected metalloproteinases by TIMP‑3. All enzyme assays were conducted in TNC 
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 10 mM  CaCl2, 0.05% Brij-35 and 0.02%  NaN3) at 37 °C, using a 
Gemini microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA). Activities of MMP-1ΔC and 
MMP-13 were measured using the fluorescent quenched peptide substrate (7-methoxycoumarin-4-yl)acetyl-Pro-
Leu-Gly-Leu-(N-3-2,4-dinitrophenyl-l-2,3-diaminopropionyl)-Ala-Arg-NH2 (Mca-PLGL-Dpa-AR) at 1.5 μM 
final  concentration28. Activity of MMP-3ΔC was measured using the fluorescent quenched substrate NFF-3, 
Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(2,4-dinitrophenyl)-NH2 at 1.5 μM final  concentration29. The 
activity of ADAMTS-4 was monitored using the fluorescent peptide substrate carboxyfluorescein-Ala-Glu~Leu-
Asn-Gly-Arg-Pro-Ile-Ser-Ile-Ala-Lys-N,N,N′,N′-tetramethyl-6-carboxyrhodamine (FAM-AE∼LQGRPISIAK-
TAMRA) at a final concentration of 0.5 μM30. The activity of ADAMTS-5 was monitored using the fluorescent 
peptide substrate ortho- aminobenzoyl-Thr-Glu-Ser-Glu~Ser-Arg-Gly-Ala-Ile-Tyr-(N-3-2,4-dinitrophenyl-L-
2,3-diaminopropionyl)-Lys-Lys-NH2 [Abz-TESE∼SRGAIY-Dpa-KK] at a final concentration of 20 μM21. The 
activity of ADAM17 was assayed using Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dpa (20 μM; Calbio-
chem, Watford, UK)31.
Ki values of TIMP-3 for various metalloproteinases were determined under equilibrium kinetic  conditions32, 
as previously described in Ref. 21. Final enzyme concentrations for Ki determinations were as follows: MMP-1ΔC 
and MMP-3ΔC were used at 1 nM; MMP-13 at 0.1 nM, and ADAMTS-4 and -5 were used at 0.5 nM; ADAM17 
was used at 1 nM. Enzymes were pre-incubated (1 h, 37 °C) with TIMP-3 (0.5–100 nM) and equilibrium rate of 
substrate hydrolysis was determined (1–18 h, 37 °C). Prism software (GraphPad, La Jolla, CA, USA) was used 
to fit the data to the tight-binding equation 32.
We observed incomplete inhibition of 1 nM MMP-1ΔC, 0.5 nM ADAMTS-4 and 0.5 nM ADAMTS-5 by 
equimolar amounts of TIMP-3, as predicted by enzyme kinetic  theory32. We thus also quantified inhibition of 
higher concentrations of these enzymes (5 nM MMP-1, 5 nM ADAMTS-4 and 10 nM ADAMTS-5) by TIMP-3 
(0.5–25 nM) using the same buffer and substrate conditions as described above.
Surface plasmon resonance analysis. The affinity of various ligands to LRP-1 was evaluated using a 
BIAcore T200 (GE, Amersham, UK). LRP-1 was immobilized on a CM5 sensor chip by amine coupling using 
N-hydroxysuccinimide (NHS), according to the manufacturer’s instructions. Immobilization was performed at 
10 μl/min until reaching a target ligand concentration of 3000 RUs on the chip. The instrument was maintained 
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at 25 °C. SPR analysis was performed in 150 mM NaCl, 10 mM CaCl2, 50 mM Tris–HCl buffer, 0.01% Tween-20, 
pH 7.5, at a flow rate of 30 μl/min. After each cycle, the sensor chip was regenerated by injecting 30 μl of 10 mM 
glycine–HCl buffer, pH 2.5. All ligands were injected over the immobilized LRP-1 at 6 concentrations ranging 
from 0 to 80 nM (except BSA which was used as a negative control and injected at up to 2 μM; MMP-1ΔC that 
was injected at up to 2 μM; and MMP-14, ADAM-10 and ADAM-17 ectodomain that were injected at up to 
160 nM). Metalloproteinase/TIMP complexes were pre-formed in vitro by incubating equimolar concentrations 
of enzyme and inhibitor for 1 h at 37 °C. Complexes were injected at 5 different concentrations (5 nM, 10 nM, 
20 nM, 40 nM and 80 nM). The Ki of MMP-1 for TIMP-1, TIMP-2 and TIMP-3 is 0.38 nM, 1.03 nM and 1.1 nM 
 respectively17,22, therefore metalloproteinase/TIMP complexes should be stable at all the concentrations used 
for injection. Each determination was performed in triplicate. BIAevaluation software was used to analyze the 
resulting sensorgrams and determine the association (ka) and dissociation (kd) rate constants, and the constant 
of dissociation (KD). Binding data were fitted in a one-site binding model.
Internalization of MMP‑1/TIMP‑3 complexes. HTB94 cells were grown to confluence in DMEM 10% 
FCS, and then incubated in DMEM 0.1% FCS supplemented with 100 nM MMP-1ΔC either alone or in a com-
plex with FLAG-tagged TIMP-3 (equimolar concentrations of enzyme and inhibitor pre-incubated for 1 h at 
37 °C), in the presence or in the absence of 500 nM RAP. Cells were cultured for 12 h, then the conditioned 
medium was harvested and concentrated by TCA precipitation. Equal volumes of all samples were analyzed by 
Western blotting using the anti-MMP-1 antibody (clone 2A7.2, from Millipore) and anti-FLAG-M2 antibody 
(Sigma-Aldrich).
Expression and purification of  [35S]TIMP‑3 and  [35S]MMP‑1. [35S]TIMP-3 was prepared by meta-
bolic labelling as previously  described17. Human proMMP-1 was cloned into pCEP4 expression plasmid with 
a FLAG-tag between the signal and prodomain.[35S]MMP-1 was generated by a modification of the protocol 
for  [35S]TIMP-3 17. HEK-293/EBNA cells transfected with proMMP-1/pCEP4 were grown to confluence in a 
150 cm2 flask, washed once and starved for 2 h in serum-free DMEM without l-glutamine, cysteine, methionine 
or cysteine. Cells were then grown for a further 4 days in serum-free DMEM without l-glutamine, cysteine, 
methionine or cysteine, and supplemented with  [35S]Met/[35S]Cys (500 μCi of Redivue Pro-Mix L-[35S] in vitro 
Cell Labelling Mix, GE Healthcare, Buckinghamshire, UK). Conditioned media were collected after 4 days, cen-
trifuged to remove cell debris and applied to a 2 ml anti-FLAG M2-agarose column (Sigma-Aldrich, Dorset, 
UK). The resin was washed extensively in TNC buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 10 mM  CaCl2]. 
Bound  [35S]proMMP-1 was eluted with 200 μg/ml FLAG peptide (Sigma-Aldrich, Dorset, UK). After elution 
with FLAG peptide,  [35S]proMMP-1 was activated with APMA as previously  described27. Cleavage of the pro-
domain was confirmed by SDS-PAGE, and the pro-domain was removed using a PD10 desalting column (GE, 
Amersham, UK). The active concentration of  [35S]MMP-1 was determined by titration against a known concen-
tration of the N-terminal domain of TIMP-3 (N-TIMP-3).
Endocytosis of  [35S]TIMP‑3,  [35S]MMP‑1 and MMP‑1/TIMP‑3 complexes. HTB94 cells were 
plated at a density of 1 × 106 cells/well, rested overnight and then washed with serum-free DMEM. Cells were 
then incubated for up to 24 h with either 10 nM  [35S]TIMP-3 or 10 nM  [35S]TIMP-3/enzyme complexes, pre-
formed in vitro by incubating  [35S]TIMP-3 and enzyme for 1 h at 37 °C. At specified times, the conditioned 
media were removed and 5% (v/v) trichloroacetic acid (TCA) added (4 °C, overnight). The TCA-soluble fraction 
(2 ml) was separated from the TCA-insoluble fraction by centrifugation (13,000 rpm, 15 min, 4 °C). The TCA-
insoluble pellet was dissolved in 1 N NaOH (500 μl). The cell layer was washed with ice-cold PBS and solubilized 
in 1 N NaOH [1 ml, 1 h, room-temperature (RT)]. Each fraction was mixed with 3 ml of scintillant (Gold-
star Multipurpose Liquid Scintillation Cocktail, Meridian, Surrey, UK) and radioactivity counted. TCA-soluble 
radioactivity present in the  [35S]TIMP-3 preparation prior to incubation with cells (5–15% of total radioactivity) 
was subtracted from the amount of TCA-soluble radioactivity at each time point. The amount of radioactivity 
in the different fractions was calculated as a percentage of the total amount of  [35S]TIMP-3 radioactivity added 
to the cells. Endocytosis of  [35S]MMP-1 and  [35S]MMP-1/TIMP complexes was evaluated in a similar manner.
Results
TIMP‑3 forms stable complexes with selected metalloproteinases in the low nanomolar 
range. In order to analyze the binding of TIMP-3/MMP complexes to LRP-1, we first investigated the inhi-
bition of selected metalloproteinases by TIMP-3 in the low nanomolar range. This allowed us to evaluate the 
lowest concentration at which these metalloproteinases and TIMP-3 form a stable complex. Generally, enzyme 
kinetic theory and experimental observation indicate that incomplete inhibition is seen at concentrations near 
the Ki value, while complete inhibition is observed at enzyme and inhibitor concentrations higher than 5 times 
the Ki  value32. We determined a Ki(app) for TIMP-3 inhibition of MMP-1ΔC of 1.86 nM (Table 1), in agreement 
with previous  reports21,33, meaning that around 50% of enzyme activity was blocked by equimolar amounts of 
enzyme. However, when enzyme concentrations were increased to 5 nM, 90% of MMP-1 activity was blocked 
by an equimolar amount of TIMP-3, indicating that the large majority of the enzyme is in a stable complex with 
the inhibitor (Fig. 1A).
TIMP-3 bound to MMP-3ΔC and MMP-13 even more tightly, with 5 nM TIMP-3 completely blocking the 
activity of 1 nM MMP-3ΔC and 0.1 nM MMP-13 (Fig. 1B–C). For MMP-3ΔC, we calculated a Ki(app) value of 
0.55 nM (Table 1) in agreement with previous  reports21,33, but for MMP-13, the Ki value was too low for accurate 
determination by this method, as has been previously  described34.
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Table 1.  Ki(app) values (M) for TIMP-3 inhibition of selected metalloproteinases. Ki(app) given as 
mean ± standard deviation (n = 3–4).
MMP-1ΔC (1 nM) 1.86E−9 ± 1.31E−10
MMP-3ΔC (1 nM) 5.50E−10 ± 4.48E−11
MMP-13 (0.1 nM) < 0.5 nM
ADAMTS-4 (0.5 nM) 1.24E−10 ± 3.95E−11
ADAMTS-5 (0.5 nM) 1.91E−09 ± 3.54E−11
ADAM17 (1 nM) 3.61E−09 ± 8.92E−11
Figure 1.  TIMP-3 forms stable complexes with selected metalloproteinases in the low nanomolar range. 
Selected metalloproteinases (A MMP-1 at 5 nM; B MMP-3ΔC at 1 nM; C MMP-13 at 0.1 nM; D ADAMTS-4 
at 5 nM; E. ADAMTS-5 at 10 nM; F ADAM17 at 1 nM) were incubated with TIMP-3 (1 h, 37 °C), and residual 
activity plotted. For each analysis, data are representative of 2–4 separate experiments with similar results.
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The activity of 5 nM ADAMTS-4 was inhibited by the same concentration of TIMP-3 (Ki(app) of 1.24 nM) 
(Table 1, Fig. 1D). Similarly, 10 nM TIMP-3 fully inhibited the activity of 10 nM ADAMTS-5 (Ki(app) of 1.91 nM, 
Table 1, Fig. 1E). TIMP-3 inhibited ADAM17 with a Ki(app) of 3.61 nM (Table 1), with 5 nM TIMP-3 being able 
to largely block the activity of 1 nM ADAM17 (Table 1, Fig. 1F).
In conclusion, these enzymatic assays demonstrated that TIMP-3 and a number of its target metalloprotein-
ases form stable complexes in vitro at concentrations in the very low nanomolar range. To analyze binding to 
LRP-1 and endocytosis of the metalloproteinase/TIMP-3 complexes, we thus selected to incubate the metallo-
proteinases with TIMP-3 at concentrations of 5 nM and above to ensure stable complex formation.
TIMP‑3 bridges the binding of metalloproteinases to LRP‑1 in vitro. We have previously shown 
that TIMP-3 directly binds to LRP-1 using  ELISA17. In order to understand this interaction in greater detail, we 
used surface plasmon resonance to determine the affinity of TIMP-3 for LRP-1 immobilised on a BIAcore sensor 
chip. Receptor-associated protein (RAP), which is a well-established LRP-1  ligand35,36, was used as positive con-
trol for binding. We measured a KD of 0.6 nM (Table 2), in good agreement with the previous determination of 
Lee and colleagues, who reported a KD of 1.4 nM for this  interaction37. The negative control, BSA, did not show 
any binding at concentrations up to 2 μM. TIMP-3 bound to LRP-1 with high affinity (KD = 1.68 nM, Table 2, 
Fig.  2A). The N-terminal domain of TIMP-3 (N-TIMP-3) bound to LRP-1 with a KD of 5.65  nM (Table  2), 
confirming that the minimal binding determinants reside in the N-terminal domain of the inhibitor. This is in 
line with our previous finding that N-TIMP-3 is endocytosed by chondrosarcoma cells in an LRP-1-dependent 
manner with similar kinetics to that of TIMP-317. TIMP-1 and TIMP-2 also bound to LRP-1, albeit with 18-fold 
and 16-fold lower affinities respectively (Table 2).
MMP-1 is a new LRP-1 ligand—Because MMP-1 undergoes autocatalysis at room temperature, we used a 
catalytically inactive form of MMP-1 [MMP-1 (E200A)] to investigate binding of this enzyme to LRP-1. SPR 
Table 2.  Kinetics of ligand binding to LRP-1 measured by SPR. LRP-1 was immobilized on a CM5 sensor 
chip and the binding constant of different analytes were determined. Each determination was performed in 
triplicate at six concentration for each analyte [0–80 nM except ADAMTS4-2 (0–180 nM), BSA, MMP-1ΔC 
and MMP-14 ectodomain (0–2 μM)]. Binding constants were calculated using the BIOevaluation software.
Ligand ka  (105)  M−1 s−1 kd  (10–3) (s-−1) KD  (10–9) (M)
RAP 68.8 4.19 0.60
TIMP-3 23.1 3.89 1.68
N-TIMP-3 5.67 3.21 5.65
TIMP-1 3.53 10.9 30.9
TIMP-2 1.04 2.82 27.1
MMP-1 E/A 1.36 4.68 34.6
MMP-1 ΔC No binding No binding No binding
MMP-1/TIMP-3 4.61 2.28 4.96
MMP-1 ΔC /TIMP-3 3.96 2.54 6.42
MMP-1/TIMP-1 3.90 6.40 16.5
MMP-1/TIMP-2 4.19 3.27 7.80
MMP-1/N-TIMP-3 5.73 2.46 4.30
MMP-13 E/A 2.34 5.98 25.6
MMP-13/TIMP-3 8.82 2.95 3.35
MMP-13/TIMP-1 3.26 3.45 10.6
MMP-13/TIMP-2 4.31 2.41 5.59
MMP-14 No binding No binding No binding
MMP-14/TIMP-3 7.85 2.32 2.95
MMP-14/TIMP-1 No binding No binding No binding
MMP-14/TIMP-2 No binding No binding No binding
ADAMTS5-2 29.9 6.78 2.27
ADAMTS5-4 6.55 5.47 8.35
ADAMTS4-2 0.49 3.81 77.56
ADAMTS5-2/TIMP-3 4.57 2.06 4.5
ADAMTS5-4/TIMP-3 6.80 2.03 3.00
ADAMTS4-2/TIMP-3 6.59 2.17 3.30
ADAM-10 -No binding No binding No binding
ADAM-17 No binding No binding No binding
ADAM-10/TIMP-3 4.46 3.86 8.67
ADAM-17/TIMP-3 5.57 3.81 6.84
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analysis showed that MMP-1 (E200A) bound to LRP-1 with a KD of 34.6 nM (Table 2). The MMP-1 catalytic 
domain (MMP-1ΔC) showed no binding to LRP-1 even at micromolar concentrations (Table 2), indicating that 
the hemopexin domain is required for binding of MMP-1 to the receptor. This is in agreement with previous stud-
ies showing that the hemopexin domain of MMP-9 mediates the majority of MMP-9 interaction with LRP-138.
TIMPs facilitate binding of MMP-1 and MMP-13 to LRP-1 in vitro—Emonard et al. reported that the pro-
MMP-2/TIMP-2 complex has a higher affinity for LRP-1 than either pro-MMP-2 or TIMP-2  alone8. We thus 
investigated whether interaction with TIMP-1, TIMP-2 or TIMP-3 could increase MMP-1 binding to LRP-1. 
MMP-1/TIMP complexes were made in vitro by incubating equimolar concentrations of MMP-1 and TIMPs 
(5–80 nM) for 1 h at 37 °C before addition to immobilised LRP-1. Previously reported Ki values for MMP-1 
inhibition by TIMP-1 and TIMP-2, which are 0.38 nM and 1.03 nM respectively, are similar to that of TIMP-3, 
indicating that complexes formed by MMP-1 with all 3 of these TIMPs remain stable at the concentrations used, 
since these are all well above the Ki  values17,22. Interaction with TIMP-3 increased MMP-1 affinity for LRP-1 
by sevenfold, to a KD of 4.96 nM (Table 2, Fig. 2B). MMP-1ΔC had no detectable affinity for LRP-1 on its own, 
but when in complex with TIMP-3, a KD of 6.42 nM was detected (Table 2), indicating that TIMP-3 is largely 
responsible for the binding of this complex to LRP-1. To further prove that formation of a complex with TIMP-3 
is necessary for its binding to LRP-1, we exogenously added MMP-1ΔC either alone or in a complex with TIMP-3 
to HTB94 chondrosarcoma-like cells and analyzed its uptake from the conditioned media after 12 h. In agree-
ment with the SPR results, MMP-1ΔC, which had no affinity for LRP-1, was not taken up by cells (Fig. 2C). In 
contrast, when the enzyme was complexed to TIMP-3, both MMP-1ΔC and TIMP-3 were internalized by cells. 
The LRP-1 inhibitor RAP inhibited this process. Altogether, these results indicate that MMP-1ΔC can only bind 
to and be internalized by LRP-1 when in a complex with TIMP-3.
Interaction with TIMP-1 and TIMP-2 also increased MMP-1 affinity for LRP-1, by 2- and 4.5-fold respectively. 
Unlike for TIMP-3, the affinities of the complexes are higher than that for TIMP-1 or TIMP-2 alone (Table 2), 
Figure 2.  Binding of TIMP-3 to LRP-1 and its internalization by HTB94 cells. A, B Sensograms from a surface 
plasmon resonance analysis of the interaction between immobilized LRP-1 and TIMP-3 or MMP-1/TIMP-3, 
passed over a chip at different concentrations (0–80 nM). C Conditioned medium containing MMP-1ΔC or 
MMP-1ΔC /TIMP-3 complex was added to HTB94 cells in the presence or absence of 500 nM RAP, harvested 
at the time points indicated and analyzed by Western blotting. D  [35S]TIMP-3 (10 nM) added to HTB94 
chondrosarcoma cells, and radioactivity in different cell fractions monitored over time (n = 3).
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suggesting that MMP-1 either contributes to the binding, or that it stabilises a TIMP-1/-2 conformation with 
increased LRP-1 affinity.
TIMPs were also able to promote binding of other MMPs to LRP-1. To study MMP-13, which undergoes 
autodegradation at room temperature, we used a catalytically inactive mutant, namely MMP-13 (E204A). This 
collagenase had a KD value of 25.6 nM for LRP-1 (Table 2). Interaction with TIMP-3 increased its affinity for 
LRP-1 by 7.6-fold, while interaction with TIMP-1 or TIMP-2 increased its affinity by 2.4- and 4.6-fold respec-
tively. (Table 2). The ectodomain of MMP-14 showed no detectable binding to LRP-1 even at micromolar con-
centrations. Incubation with TIMP-3 facilitated binding with a KD of 2.95 nM, while incubation with TIMP-1 
or TIMP-2 did not detectably improve affinity (Table 2).
TIMP-3 increases the affinity of ADAMTS-4 and deletion mutants of ADAMTS-5 for LRP-1—The aggrecanase 
ADAMTS-5 is an LRP-1 ligand, with the LRP-1-binding determinants localized in the ancillary domains of the 
enzyme. Affinity for LRP-1 thus decreases with consecutive deletion of the non-catalytic C-terminal  domains13,14. 
Here, we found that ADAMTS-5 lacking the C-terminal thrombospondin domain (ADAMTS5-2) bound effec-
tively to LRP-1, with a KD of 2.27 nM. Deletion of the cysteine-rich and spacer domain (ADAMTS5-4) reduced 
the affinity of ADAMTS-5 for LRP-1 to 8.35 nM. Binding to TIMP-3 had little effect on ADAMTS5-2 affinity 
for LRP-1 (KD increased to 4.5 nM), but improved ADAMTS5-4 affinity for LRP-1 (KD = 3.00 nM) (Table 2).
ADAMTS-4 had lower affinity for LRP-1 (KD = 77.56 nM) than ADAMTS-5 (KD = 2–8 nM) (Table 2). Bind-
ing to TIMP-3 improved the KD to 3.3 nM, indicating that TIMP-3 can also mediate ADAMTS-4 scavenging.
TIMP-3 also improved affinity of ADAM10 and ADAM17 for LRP-1—Binding of LRP-1 was undetectable for 
the free form of either ADAM10 or ADAM17, while binding to TIMP-3 improved their affinity markedly, with 
KD values of 8.67 for ADAM10/TIMP-3 and 6.84 for ADAM17/TIMP-3. This suggests that TIMP-3 can facilitate 
the binding of these enzymes to LRP-1.
In conclusion, a systematic SPR analysis showed that TIMP-3 binds to LRP-1 with the highest affinity among 
TIMPs. TIMPs generally increased affinity of the binding of specific collagenases (MMP-1 and -13) to LRP-1, 
with TIMP-3 mediating this process to the greatest extent.
Complex formation with metalloproteinases does not affect the kinetics of TIMP‑3 endocyto-
sis. TIMP-3 is rapidly internalized by various cell types via LRP-1.[35S]radiolabeling of TIMP-3 and subse-
quent detection of radioactivity in different cell compartments has been used to follow TIMP-3  endocytosis17. 
We used this method to investigate whether complex formation with metalloproteinases had an effect on the rate 
of  [35S]TIMP-3 endocytosis.[35S]TIMP-3/metalloproteinase complexes were generated in  vitro by incubating 
10 nM  [35S]TIMP-3 with an equimolar concentration of various metalloproteinases for 1 h at 37 °C. Forma-
tion of 1:1 stoichiometric complexes and their stability over 24 h were confirmed by measuring their activity 
against specific synthetic substrates. As previously  shown17, levels of  [35S]TIMP-3 in the TCA insoluble fraction 
of the conditioned media (containing intact not yet internalized  [35S]TIMP-3) decreased over time, while cell-
associated  [35S]TIMP-3  ([35S]TIMP-3 inside the cells after internalization) and  [35S]TIMP-3 in the TCA-soluble 
fraction of the conditioned media  ([35S]TIMP-3 released into the media after internalization and lysosomal deg-
radation) increased over time (Fig. 2D).[35S]TIMP-3/MMP-1 complex was internalized with indistinguishable 
kinetics compared to  [35S]TIMP-3 alone (Fig. 3A). Similar results were obtained when  [35S]TIMP-3 was in com-
plex with MMP-1ΔC, which had no affinity at all for LRP-1 in vitro (Fig. 3A). In addition to full-length MMP-1 
and MMP-1ΔC, clearance of  [35S]TIMP-3 was not affected when the inhibitor was in complex with MMP-3ΔC, 
MMP-9 or MMP-14 ectodomain (Fig. 3B). Then KD of TIMP-3 for LRP-1 when in complex with ADAMTS5-2 
or ADAMTS4-2 was similar to that of TIMP-3 alone. In agreement, complex formation with ADAMTS5-2 or 
ADAMTS4-2 did not significantly affect the internalization kinetics and clearance of  [35S]TIMP-3 (Fig. 3C, D).
In conclusion, the internalization rate of TIMP-3 is not affected by complex formation with metalloprotein-
ases, suggesting that the inhibitor can drive the internalization of TIMP-3/metalloproteinase complexes.
MMP‑1 is endocytosed by cells and TIMP‑3, but not other TIMPs, increases its endocytosis 
rate. SPR analysis showed that MMP-1 directly binds to LRP-1 through its hemopexin domain, suggest-
ing that it could be internalized in an LRP-1-dependent manner, similarly to other MMPs, including MMP-2, 
MMP-9 and MMP-138,9,11. Thus, in order to investigate whether MMP-1 could be internalized in a cellular sys-
tem, it was metabolically radiolabelled with  [35S], purified and 10 nM  [35S]MMP-1 incubated with HTB94 cells. 
Levels of intact  [35S]MMP-1 in the conditioned media decreased by about 20% over 24 h, while  [35S]MMP-1 
inside the cells and in the TCA-soluble fraction  ([35S]MMP-1 fragments deriving from lysosomal degradation 
and released into the conditioned media) increased over the time, indicating that MMP-1 is indeed internalized 
by cells, although at lower rate compared to TIMP-3 and in agreement with their different KD values for LRP-1 
(Fig. 4A and E). Conversely, when 10 nM  [35S]MMP-1 was pre-incubated with an equimolar concentration of 
TIMP-3 to form a  [35S]MMP-1/TIMP-3 complex, its internalization increased, showing endocytosis kinetics 
similar to that of  [35S]TIMP-3 alone (Fig. 4B and E). Neither TIMP-1 nor TIMP-2 promoted  [35S]MMP-1 endo-
cytosis under these experimental conditions (Fig. 4C–E). Indeed, at concentrations used in this assay, MMP-1/
TIMP-1 and MMP-1/TIMP-2 complexes had reduced binding to LRP-1 on SPR compared to an equal concen-
tration of MMP-1/TIMP-3 complexes (Fig. 4F).
In conclusion, we identified MMP-1 as a novel LRP-1 ligand that, similarly to other metalloproteinases, is 
actively endocytosed and degraded by cells. TIMP-3, but not TIMP-1 or TIMP-2, increased MMP-1 internaliza-
tion rate when in complex with the proteinase.
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Discussion
Two classes of metalloproteinases, MMPs and ADAMTSs, play a central role in ECM turnover, together with 
the ADAMs that are majorly involved in ectodomain shedding of cell-surface components. The activity of these 
enzymes is finely regulated by their endogenous inhibitors, known as TIMPs. LRP-1 is an endocytic receptor 
that has been reported to mediate the internalization and degradation of a number of MMPs, ADAMTSs and 
TIMPs, thus functioning as a master regulator of ECM  turnover8,9,11,13–15,17. Levels of these proteins in the ECM 
can tightly correlate to their affinity for the receptor. For example, TIMP-3, which was reported to bind to LRP-1 
with high affinity, is hardly found extracellularly unless its interaction with LRP-1 and subsequent endocytosis 
are  prevented17,39. Investigating affinities for LRP-1 of different metalloproteinases, TIMPs and metalloprotein-
ase/TIMP complexes can provide useful information about turnover of these proteins and potential effects on 
ECM turnover.
Figure 3.  Internalization of TIMP-3 in complex with a number of MMPs and ADAMTSs.[35S]TIMP-3 was 
incubated with either MMP-1, MMP-1ΔC, MMP-3, MMP-9, MMP-14, ADAMTS4-2 or ADAMTS5-2 for 1 h at 
37 °C to make a complex in vitro. A HTB94 cells were incubated with either  [35S]TIMP-3 alone (solid squares, 
solid black line) or  [35S]TIMP-3/MMP-1 complex (open circles, black dashed line) or  [35S]TIMP-3/MMP-1ΔC 
complex (open triangles, dotted black line). At indicated time points intact  [35S]TIMP-3 in the conditioned 
media was measured. B Clearance of  [35S]TIMP-3 after 24 h incubation with HTB94 cells was evaluated for the 
inhibitor alone or in complex with MMP-1, MMP-1ΔC MMP-3, MMP-9 and MMP-14 catalytic domain and 
shown as mean values of intact  [35S]TIMP-3 remained in the media ± standard deviation (analyzed by one-way 
ANOVA, followed by Dunnett’s multiple comparisons test where  [35S]TIMP-3 was taken as a control; ns non 
significant; n = 3). Values for  [35S]TIMP-3,  [35S]TIMP-3/MMP-1 and  [35S]TIMP-3/MMP-1ΔC were extrapolated 
from panel A (symbols inside the black box). C Similar analysis was performed for  [35S]TIMP-3 alone (solid 
squares, black solid line) or  [35S]TIMP-3/ADAMTS4-2 complex (black dashed line and open circles) or  [35S]
TIMP-3/ADAMTS5-2 (black dotted line and open triangles). D Clearance of  [35S]TIMP-3 alone  [35S]TIMP-3/
ADAMTS4-2 or  [35S]TIMP-3/ADAMTS5-2 after 24 h was extrapolated from panel C (symbols inside the black 
box), and represented as mean values of intact  [35S]TIMP-3 remained in the media ± standard deviation and 
analyzed by one-way ANOVA, followed by Dunnett’s multiple comparisons test where  [35S]TIMP-3 was taken as 
a control; ns non significant; n = 3).
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In the current study, we used SPR to systematically analyze LRP-1 interaction with a number of MMPs, 
ADAMs, ADAMTSs, TIMPs and metalloproteinase/TIMP complexes. We found that, among these proteins, 
TIMP-3 bound to LRP-1 with highest affinity. Furthermore, TIMP-3 increases the affinity for LRP-1 of tar-
get proteinases that bind to LRP-1 by themselves, such as MMP-1, MMP-13 and ADAMTS-4, but also that 
of metalloproteinases, including MMP-14, ADAM10 and ADAM17, which have no affinity for the receptor. 
ADAMTS-5 binds to and is rapidly endocytosed by LRP-114, and we found that the affinity of ADAMTS-5 lacking 
the C-terminal thrombospondin domain (ADAMTS5-2) for the receptor was similar to that of TIMP-3. After 
secretion, ADAMTS-5 is extracellularly processed to truncated forms that acquire distinct features from the full-
length  counterpart40,41, including different LRP-1 affinities and endocytosis  rates13. Expression and purification 
of recombinant full-length ADAMTS-5 is inefficient, so we did not analyze the full-length enzyme in this study. 
While TIMP-3 had little effects on the affinity of ADAMTS-5 for LRP-1, it doubled the affinity of a truncated 
form of ADAMTS-5 lacking of the cysteine-rich and spacer domain (ADAMTS5-4) for the receptor, suggesting 
TIMP-3 may promote scavenging of smaller, degraded forms of the enzyme.
Similarly to TIMP-3, TIMP-1 and TIMP-2 directly bound to LRP-1, although with lower affinities. Both 
TIMP-1 and TIMP-2 increased the affinities of MMPs for LRP-1, but not to the same extent as TIMP-3. This 
indicates that there are at least two modes by which inhibitors can increase proteinase affinity for LRP-1. In the 
simplest case, binding may be mediated primarily through residues on the inhibitor, such that the inhibitor/
proteinase complex has similar affinity for LRP-1 as the free inhibitor alone. Such behaviour was observed for 
TIMP-3, with TIMP-3/MMP-13, TIMP-3/MMP-1 and TIMP-3/MMP-14 complexes having similar affinity for 
LRP-1 as free TIMP-3. We demonstrated that this mode of binding is able to support biologically relevant bridg-
ing of the MMP to LRP-1, as TIMP-3 was able to promote MMP-1 endocytosis by HTB94 chondrosarcoma cells.
Alternatively, the proteinase-inhibitor complex may bind with higher affinity than either protein alone. We 
observed that TIMP-1 and TIMP-2 complexes with both MMP-1 and MMP-13 had ~ 2–fivefold higher affinity 
for LRP-1 than any of the four proteins alone. This is in line with what has been reported for the proMMP-2/
TIMP-2 complex, which has ~ tenfold higher affinity for LRP-1 than either component  alone8. This may be due 
to a conformational change induced by proteinase-inhibitor interaction, as is the case with α2-macroglobulin, 
which has low affinity for LRP-1 in its free form, but which undergoes a conformational change upon proteinase 
binding that increases affinity of the complex for LRP-1. Alternatively, both enzyme and inhibitor may directly 
participate in LRP-1 binding, each contributing a lysine residue to form the minimal LRP-1 binding  unit35. We 
consider this the more likely mechanism, as TIMPs are considered to be conformationally stable, with only minor 
structural rearrangements upon interaction with MMPs. However, this mode of binding appears to be insufficient 
to support bridging to LRP-1 in a complex biological environment, as we found that neither TIMP-1 nor TIMP-2 
could increase the rate of MMP-1 endocytosis by HTB94 chondrosarcoma cells. Thus, our kinetic data indicate 
that TIMP-3 bridges MMP binding to LRP-1 though a different mechanism to that of TIMP-1 and TIMP-2, and 
that only TIMP-3 can promote scavenging of these target enzymes from the extracellular environment.
The observation that TIMP-3/metalloproteinase complexes and free TIMP-3 have similar affinity for LRP-1 
to that of TIMP-3 alone suggests that TIMP-3 interacts with LRP-1 through a site distinct from its inhibitory 
ridge. Studies of a number of LRP-1 ligands suggest that a pair of basic residues is responsible for binding to 
acidic pockets on the complement-type repeats (CRs) of the  receptor42,43. For example, extensive mutagenesis 
and crystallography studies indicate that RAP binds to LRP-1 via two lysine residues, K256 and K270, which are 
located 22 Å apart on the surface of the  molecule35. TIMP-3 contains a cluster of lysine and arginine residues 
situated on the opposite side to the inhibitory ridge. This basic region mediates binding to sulfated proteoglycans 
of the extracellular  matrix44. We previously found that heparin blocks TIMP-3 binding to LRP-117, suggesting 
that the heparin-binding and LRP-1-binding sites of TIMP-3 overlap, and supporting the postulate that the 
metalloproteinase-inhibitory region of TIMP-3 is spatially separated from the LRP-1-binding and overlapping 
ECM-binding basic region.
There is emerging evidence that metalloproteinases have functions other than proteolytic cleavage, and 
that these functions are often related to their non-catalytic domains. For example, a non-catalytic C-terminal 
fragment of MMP-12 has been shown to have antimicrobial  activity45. ADAMTS-1 and ADAMTS-4 display 
anti-angiogenic properties through their ability to bind VEGF and sequester it from  VEGFR46,47. Fragments 
of ADAMTS-5 derived from its ancillary domains have been shown to be anti-tumorigenic both in vitro and 
in vivo48. ADAMTS-12 modulates neutrophil apoptosis, likely by interacting with CD36 and CD47 through its 
thrombospondin  domains49. Although it has not been explicitly demonstrated, it is likely that at least some of 
these non-catalytic functions are maintained when metalloproteinases interact with TIMPs. In addition to its role 
in inhibiting the proteolytic activity of target metalloproteinases, TIMP-3 may thus also inhibit non-proteolytic 
activities of target proteinases by facilitating their LRP-1-mediated endocytosis. This would position TIMP-3 as 
a central regulator of metalloproteinase levels and activity in the extracellular environment.
It is interesting to speculate that competition between different TIMPs for metalloproteinases could lead to 
diverse biological responses. TIMP-1 and TIMP-2 would serve primarily to inhibit the catalytic activity of the 
proteinases, but would not facilitate their endocytic clearance. TIMP-3, on the other hand, is uniquely able to 
address the enzymes to intracellular degradation and therefore regulate both their proteolytic and non-proteolytic 
functions. We found that TIMP-3 also bridges binding of members of the ADAM and ADAMTS families to 
LRP-1. The ectodomains of ADAM10 and ADAM17 do not interact with the receptor unless they are in complex 
with TIMP-3. This may explain why TIMP-3 decreases cell surface levels of  ADAM1050.
In conclusion, this work shows that TIMP-3 can promote LRP-1-mediated endocytosis of target metallo-
proteinases by facilitating their binding to LRP-1. As such, TIMP-3 can inhibit both proteolytic-dependent and 
-independent activities of metalloproteinases in the extracellular environment.
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